Skip to content

Study · Randomized controlled trial · n = 87 · 2024

4 results

Sex differences in response to intranasal oxytocin as an adjunctive therapy for patients with severe mental illness.

Maoz H, Grossman-Giron A, Baruch N, Sedoff O, Mama Y, Nitzan U, Tzur Bitan D

Psychiatry research14 Nov 2024Cited by 4 (Europe PMC)

PMID39579479 (opens in a new tab)DOI10.1016/j.psychres.2024.116269 (opens in a new tab)PepBankPUB-39579479
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In inpatients with severe mental illness, sex moderated the effect of intranasal oxytocin versus placebo on the Hamilton Rating Scale for Depression.

    In plain wordsIn inpatients with severe mental illness, the effect of oxytocin spray on depression scores, compared with placebo, differed between men and women.

    Peptide
    Oxytocin
    Outcome
    MixedSex moderation of oxytocin effect on Hamilton Rating Scale for Depression
    Study

    n = 87

    Comparator
    Placebo
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    32IU twice daily · intranasal · four weeksAs given in this study (human).

    Source sentences

    Summary
    Sex moderated the effect of OT/PLC on the Hamilton Rating Scale for Depression (HRDS) (p < 0.001).
    2 context sentences
    Summary · context
    A secondary analysis was conducted on a previously studied group of patients who participated in a double-blind, placebo-controlled trial evaluating the impact of INOT as an add-on treatment for patients with SMI.
    Summary · context
    Patients treated in inpatient settings (N = 87) received twice-daily INOT (32IU) or placebo (PLC) for a period of four weeks.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In female inpatients with severe mental illness, intranasal oxytocin gave greater reductions in depression symptoms and severity than placebo.

    In plain wordsIn women with severe mental illness, oxytocin spray reduced depression symptoms more than placebo did.

    Peptide
    Oxytocin
    Outcome
    DecreaseDepression symptoms (HRDS) in females
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    32IU twice daily · intranasal · four weeksAs given in this study (human).

    Source sentences

    Summary
    A significant effect for sex was found in the Hopkins Symptom Checklist-short form (HSCL-11) (p = 0.04) and HRDS (p < 0.001), with females showing greater reductions in anxiety and depression symptoms and severity.
    2 context sentences
    Summary · context
    A secondary analysis was conducted on a previously studied group of patients who participated in a double-blind, placebo-controlled trial evaluating the impact of INOT as an add-on treatment for patients with SMI.
    Summary · context
    Patients treated in inpatient settings (N = 87) received twice-daily INOT (32IU) or placebo (PLC) for a period of four weeks.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In female inpatients with severe mental illness, intranasal oxytocin gave greater reductions in anxiety symptoms on the HSCL-11 than placebo.

    In plain wordsIn women with severe mental illness, oxytocin spray reduced anxiety symptoms more than placebo did.

    Peptide
    Oxytocin
    Outcome
    DecreaseAnxiety symptoms (HSCL-11) in females
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    32IU twice daily · intranasal · four weeksAs given in this study (human).

    Source sentences

    Summary
    A significant effect for sex was found in the Hopkins Symptom Checklist-short form (HSCL-11) (p = 0.04) and HRDS (p < 0.001), with females showing greater reductions in anxiety and depression symptoms and severity.
    2 context sentences
    Summary · context
    A secondary analysis was conducted on a previously studied group of patients who participated in a double-blind, placebo-controlled trial evaluating the impact of INOT as an add-on treatment for patients with SMI.
    Summary · context
    Patients treated in inpatient settings (N = 87) received twice-daily INOT (32IU) or placebo (PLC) for a period of four weeks.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In male inpatients with severe mental illness, intranasal oxytocin did not reduce anxiety and depression symptoms compared with placebo.

    In plain wordsIn men with severe mental illness, oxytocin spray did not reduce symptoms compared with placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeAnxiety and depression symptoms in males
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    32IU twice daily · intranasal · four weeksAs given in this study (human).

    Source sentences

    Summary
    A significant effect for sex was found in the Hopkins Symptom Checklist-short form (HSCL-11) (p = 0.04) and HRDS (p < 0.001), with females showing greater reductions in anxiety and depression symptoms and severity. This effect was not found for males.
    2 context sentences
    Summary · context
    A secondary analysis was conducted on a previously studied group of patients who participated in a double-blind, placebo-controlled trial evaluating the impact of INOT as an add-on treatment for patients with SMI.
    Summary · context
    Patients treated in inpatient settings (N = 87) received twice-daily INOT (32IU) or placebo (PLC) for a period of four weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:48 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.